Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation (NYSE: WAT), a global leader in analytical instrumentation and laboratory technologies, provides critical solutions for pharmaceutical development, food safety testing, and environmental monitoring. This dedicated news hub aggregates official announcements, financial disclosures, and strategic updates directly impacting the company's market position and technological advancements.
Investors and industry professionals will find curated updates including quarterly earnings reports, product innovation announcements, executive leadership changes, and regulatory developments. Our repository ensures timely access to filings, partnership agreements, and scientific breakthroughs related to Waters' chromatography systems, mass spectrometry platforms, and thermal analysis instruments.
Key content categories include financial performance updates, new product launches, research collaborations, and operational expansions. Bookmark this page to monitor developments affecting Waters' role in life sciences R&D, quality assurance protocols, and laboratory informatics solutions across 100+ countries.
Waters (NYSE: WAT) has reported significant progress in its sustainability commitments, exceeding its greenhouse gas emissions reduction target two years ahead of schedule with a 36% reduction from 2016 baseline. The company has achieved notable environmental milestones, including a 50% decrease in landfill waste and a 29% reduction in water use intensity.
In social initiatives, Waters expanded its STEM education efforts through the Waters Student Academy, reaching over 380 students and increasing candidate diversity in recruitment by 6%. The company introduced the University Pathways Program to support career development and diversify talent pipeline.
Waters received recognition as the 2024 Public Company Board of the Year by NACD New England Chapter and was included in Barron's 2024 100 Most Sustainable Companies. The company has committed to science-based emission reduction targets aligned with SBTi's 1.5°C criteria.
Waters (NYSE:WAT) announced its participation in the 7th Annual Evercore HealthCONx Conference. CEO Udit Batra will join a fireside chat on December 4th, 2024, at 10:00 AM Eastern Time. The event will be livestreamed on Waters' Investor Relations website, with a replay available for 90 days.
Waters is a global leader in analytical instruments and software, specializing in chromatography, mass spectrometry, and thermal analysis innovations. The company employs approximately 7,500 people worldwide, operates in 35 countries with 15 manufacturing facilities, and distributes products in over 100 countries.
Waters (NYSE:WAT) has opened a new 45,000 square foot manufacturing facility at Longbridge Business Park, UK. The facility triples the company's manufacturing footprint and enhances machining capacity for components used in mass spectrometry systems. Built to BREEAM Very Good standard with an 'A' Energy Performance Certificate rating, the facility features zero natural gas consumption for heating and maintains temperature-controlled production for sub-micron accuracy manufacturing. The expansion represents a significant investment in the region and supports Waters' Mass Spectrometry Centers in Wilmslow, UK and Wexford, Ireland.
Waters (NYSE: WAT) has announced waters_connect Data Intelligence software, a new cloud-based application designed to enhance laboratory data management and audit readiness. The software integrates with Waters Empower Chromatography Data System (CDS) to provide comprehensive business intelligence on chromatographic data. Key features include real-time audit response capabilities, risk visibility for regulatory compliance, and system suitability monitoring that could help prevent failures estimated to cost up to $600,000 annually. The software will be available for ordering in December 2024.
Waters (NYSE: WAT) reported strong Q3 2024 results with sales of $740 million, up 4% from Q3 2023. The company exceeded guidance across key metrics, with GAAP EPS of $2.71 and non-GAAP EPS of $2.93. All regions and end markets showed growth, with pharmaceutical market sales up 2%, industrial market sales increasing 9%, and academic/government market sales rising 2%. Instrument systems sales grew 1%, while recurring revenues increased 6%. The company raised its full-year 2024 guidance, expecting Q4 constant currency sales growth of 5% to 7%.
Waters (NYSE: WAT) has introduced new bioseparations tools to accelerate and improve the development of RNA-based pharmaceuticals. The comprehensive set includes:
1. Novel digestion enzymes (RapiZyme MC1 and RapiZyme Cusativin) for complete RNA sequence coverage.
2. LC-MS-grade reagents (IonHance HFIP) to increase sensitivity and improve detection accuracy.
3. waters_connect MAP Sequence software for semi-automated workflows, reducing data processing time.
These tools simplify large molecule RNA analysis, supporting the development of mRNA vaccines, personalized cancer therapies, and drugs for genetic disorders. The new products aim to enhance sequence confirmation, modification analysis, and overall characterization of complex RNA molecules, potentially accelerating therapeutic development and lowering barriers for LC-MS non-experts.
Waters (NYSE:WAT) has introduced the TA Instruments™ Discovery Core Rheometer, a streamlined analyzer designed for routine manufacturing quality control and assurance laboratories. This compact system offers:
- Easy-to-use touchscreen interface with self-guided training, methods, and applications
- Superior performance at an affordable price, with up to 2x better torque sensitivity compared to similar rheometers
- Compact design requiring half the bench space of comparable modular rheometers
- Ability to handle multiple material types such as battery slurries, printing inks, food, and personal care products
The Discovery Core Rheometer is equipped with RheoGuide™ Software, providing immediate walk-up use and faster, real-time data analysis. It is orderable today, with worldwide availability in Q1 2025.
Waters (NYSE:WAT) has announced its Q3 2024 financial results conference call, scheduled for Friday, November 1st, 2024 at 8:00 a.m. Eastern Time. The call will be broadcast live via webcast on the company's Investor Relations website. A replay will be available until November 29th, 2024.
Waters is a global leader in analytical instruments and software, specializing in chromatography, mass spectrometry, and thermal analysis innovations. With a 65-year history, the company serves the life, materials, food, and environmental sciences sectors. Waters employs approximately 7,500 people worldwide, operates in 35 countries with 15 manufacturing facilities, and its products are available in over 100 countries.
Waters (NYSE:WAT) has appointed Heather Knight to its Board of Directors, effective August 14, 2024. Knight, currently serving as Executive Vice President and Group President, Medical Products and Therapies at Baxter International, brings nearly three decades of experience in the pharmaceutical and medical device industries. Her appointment is expected to enhance the board's oversight of strategy and shareholder value.
Dr. Flemming Ornskov, Chair of the Board, praised Knight's proven track record in driving growth and innovation. Dr. Udit Batra, President and CEO of Waters , highlighted Knight's commitment to operational excellence and her global experience in commercial execution and portfolio innovation as complementary to the board's existing skills.
Waters (NYSE: WAT) reported Q2 2024 financial results with sales of $709 million, exceeding guidance but declining 4% as reported and in organic constant currency. GAAP EPS was $2.40, while non-GAAP EPS was $2.63, surpassing expectations due to strong operational performance. The company experienced better-than-expected performance in China and higher M&A contribution from Wyatt.
Key highlights include:
- Ex-China organic constant currency sales growth across Pharma, Industrial, and Academic & Government end markets
- Full-year outlook adjusted for a more gradual market improvement in H2 2024
- Pharmaceutical market sales decreased 3% as reported, 4% in organic constant currency
- Industrial market sales decreased 4% both as reported and in organic constant currency
- Academic and government market sales declined 15% as reported, 16% in organic constant currency
